50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
NASDAQ:CYTK

Cytokinetics - CYTK Stock Forecast, Price & News

$50.03
+0.80 (+1.63%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.22
$50.36
50-Day Range
$38.74
$54.52
52-Week Range
$29.26
$55.80
Volume
1.29 million shs
Average Volume
1.17 million shs
Market Capitalization
$4.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.73

Cytokinetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
23.2% Upside
$61.73 Price Target
Short Interest
Bearish
12.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
0.34mentions of Cytokinetics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$6.01 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.71) to ($4.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

966th out of 1,096 stocks

Pharmaceutical Preparations Industry

476th out of 548 stocks

CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

Analyst Ratings for Cytokinetics
Cytokinetics Is Showing Its Muscles on the Charts
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
8/04/2022
Today
9/28/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
253
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$61.73
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+23.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-215,310,000.00
Net Margins
-142.85%
Pretax Margin
-142.85%

Debt

Sales & Book Value

Annual Sales
$70.43 million
Book Value
$2.91 per share

Miscellaneous

Free Float
89,437,000
Market Cap
$4.71 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 58)
    CEO, Pres & Director
    Comp: $1.08M
  • Mr. Ching W. JawMr. Ching W. Jaw (Age 59)
    Sr. VP & CFO
    Comp: $645.6k
  • Dr. Fady Ibraham Malik FACC (Age 58)
    M.D., Ph.D., Exec. VP of R&D
    Comp: $733.08k
  • Mr. Andrew M. Callos (Age 66)
    Exec. VP & Chief Commercial Officer
    Comp: $411.85k
  • Dr. James A. Spudich Ph.D. (Age 80)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Jeff Lotz
    VP of Sales & Operations
  • Mr. Robert C. Wong (Age 54)
    VP & Chief Accounting Officer
  • Ms. Joanna Siegall
    Associate Director of Corp. Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer
  • Mr. Scott R. Jordan
    Sr. VP of Global Marketing & Commercial Strategy













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2022?

10 brokers have issued twelve-month target prices for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they expect the company's stock price to reach $61.73 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2022?

Cytokinetics' stock was trading at $45.58 at the beginning of the year. Since then, CYTK shares have increased by 8.0% and is now trading at $49.23.
View the best growth stocks for 2022 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.81. The biopharmaceutical company earned $88.97 million during the quarter, compared to analysts' expectations of $3.73 million. Cytokinetics had a negative trailing twelve-month return on equity of 118.37% and a negative net margin of 142.85%. The business's revenue was up 3029.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.86) earnings per share.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (4.78%), Pictet Asset Management SA (2.58%), Lazard Asset Management LLC (1.98%), Driehaus Capital Management LLC (1.75%), Artal Group S.A. (1.35%) and Deerfield Management Company L.P. Series C (1.23%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $49.23.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $4.63 billion and generates $70.43 million in revenue each year. The biopharmaceutical company earns $-215,310,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 253 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.